Peptide News
Regulatory developments, FDA actions, and the policy stories shaping the peptide landscape.
76 articlesPatients Say Unapproved Peptides Hurt Them as the Access Debate Heats Up
A new investigation documents patients who say peptides like BPC-157 hurt them, even as the MAHA movement pushes the FDA to loosen access. Here's what the reporting found.
Read the guide → 📰 Peptide NewsGLP-1 Vision-Loss Lawsuits Are Mounting: What the Growing NAION Litigation Means
A growing wave of lawsuits alleges Ozempic, Wegovy, and Mounjaro caused a rare vision-loss condition called NAION. Here's what the claims say, what the science shows, and what's next.
Read the guide → 📰 Peptide NewsZealand Pharma's Petrelintide Hits Phase 2 Goals in Obesity and Type 2 Diabetes, ZUPREME-2 Results Show
Zealand Pharma's amylin analog petrelintide produced up to 9.2% weight loss and meaningful blood sugar improvements in a Phase 2b trial of adults with obesity and type 2 diabetes.
Read the guide → 📰 Peptide NewsNew Biomarker Data Show Lilly's Taltz-Zepbound Combination Triggers Broader Immune Changes Than Taltz Alone
Exploratory biomarker data presented at a dermatology conference show Eli Lilly's Taltz-Zepbound combination altered far more proteins and genes than Taltz alone in people with psoriasis and obesity.
Read the guide → 📰 Peptide NewsHanmi's Eppe Becomes South Korea's First Approved Domestic GLP-1 Obesity Drug
South Korea's drug regulator approved Hanmi Pharmaceutical's Eppe, the country's first homegrown GLP-1-based obesity treatment, setting up a new competitor to Wegovy and Mounjaro.
Read the guide → 📰 Peptide NewsFDA Warning Letter Cites Empower Pharmacy Over Compounded GLP-1 Products and Sterility Lapses
A newly disclosed FDA warning letter accuses one of the country's largest compounding pharmacies of selling tirzepatide and semaglutide combination products that may not qualify for compounding exemptions, alongside sterility violations.
Read the guide → 📰 Peptide NewsCVS Caremark Restores Zepbound Coverage, Adds Foundayo, as Lilly and Novo Go Co-Preferred
CVS Caremark's commercial formulary update brings Zepbound back into coverage and adds Foundayo, making Eli Lilly and Novo Nordisk GLP-1 drugs co-preferred for an estimated 25 to 30 million plan members.
Read the guide → 📰 Peptide NewsTrump Administration Weighs Temporary Stopgap to Allow Sale of Some Unapproved Peptides, Washington Post Reports
The Washington Post reports the Trump administration is drafting a temporary measure letting compounding pharmacies sell certain peptides while new FDA rules are written.
Read the guide → 📰 Peptide NewsNew Study Links GLP-1 Drugs and Unapproved Peptides to Sharply Higher Aspiration Risk Under Anesthesia
A UK study of over 47,000 surgery patients found an 11-fold higher aspiration risk among GLP-1 users, prompting an anesthesiologist group's new warning.
Read the guide → 📰 Peptide NewsViking Therapeutics Starts New VK2735 Maintenance-Dosing Study, Testing Oral and Less-Frequent Regimens
Viking Therapeutics has begun a new VK2735 study testing whether oral pills or less-frequent injections can maintain weight loss after initial treatment.
Read the guide → 📰 Peptide NewsLilly and Novo Present Early "Biological Aging" Data for Their GLP-1 Drugs at a Boston Conference
Eli Lilly and Novo Nordisk shared preliminary, company-funded biological-aging-clock data for tirzepatide and semaglutide at an October 2026 conference. Here's what was shown, and what's still missing.
Read the guide → 📰 Peptide NewsNovo Nordisk and Eli Lilly File Oral Obesity Pills for Approval in South Korea, Setting Up a Three-Way Race With Hanmi's EPPE
Novo Nordisk's Wegovy Pill and Eli Lilly's Foundayo have both been filed for approval with South Korea's drug regulator, where they'll compete against Hanmi Pharmaceutical's locally developed injectable, EPPE.
Read the guide → 📰 Peptide NewsLilly's Zepbound Shows Greater Weight Loss Than Wegovy HD in New Indirect Comparison
A new Lilly-sponsored indirect treatment comparison presented at EASD 2026 found Zepbound produced more weight loss than Wegovy HD, though the drugs weren't tested head-to-head. Here's what the numbers do and don't show.
Read the guide → 📰 Peptide NewsEcnoglutide Shows a Favorable Safety Profile in Adolescents With Obesity, New Phase 1b Data Finds
A placebo-controlled Phase 1b trial presented at EASD 2026 found Sciwind Biosciences' ecnoglutide was well tolerated in 48 adolescents with obesity, with early signs of weight and BMI reduction over 20 weeks.
Read the guide → 📰 Peptide NewsTirzepatide's SURPASS-CVOT Trial Shows Non-Inferior Heart Protection Compared to Trulicity, Full Data Presented at EASD 2026
Detailed SURPASS-CVOT results presented at EASD 2026 show tirzepatide was non-inferior to dulaglutide for cardiovascular outcomes in people with type 2 diabetes and heart disease, stopping short of proving superiority.
Read the guide → 📰 Peptide NewsReal-World OCTANE Study Tracks Patients Switching to the Oral Wegovy Pill, New Data Presented at EASD 2026
A U.S. real-world study presented at EASD 2026 looked at three-month weight outcomes for patients who switched from injectable semaglutide or tirzepatide to the oral Wegovy pill.
Read the guide → 📰 Peptide NewsWhy Lilly and Novo Are Betting Big on Amylin for the Next Wave of Obesity Drugs
Analysts project billions in future sales fromamylin-based obesity drugs like eloralintide and CagriSema, but new trial data is reviving a debate about how many patients can tolerate them.
Read the guide → 📰 Peptide NewsNew Modeling Analysis Projects Foundayo (Orforglipron) Could Cut Future Diabetes Risk by Up to 57%
A new modeling analysis of Lilly's ATTAIN-1 trial projects big reductions in predicted diabetes and heart-disease risk for Foundayo (orforglipron) — with an important caveat about what modeling can and can't show.
Read the guide → 📰 Peptide NewsFDA Warning Letters Hit Five More Peptide Sellers Over Unapproved GLP-1 and Recovery Peptide Products
The FDA sent warning letters to five U.S. peptide sellers in its latest enforcement sweep, citing unapproved marketing of semaglutide, tirzepatide, retatrutide, PT-141, and other products sold as "research use only."
Read the guide → 📰 Peptide NewsFifth Circuit Upholds FDA's Semaglutide Shortage Determination, Rejecting Compounders' Court Challenge
The Fifth Circuit Court of Appeals has affirmed the FDA's finding that the semaglutide shortage ended, upholding federal limits on compounding pharmacies making copies of Ozempic and Wegovy.
Read the guide → 📰 Peptide NewsBoehringer Ingelheim's Survodutide Hits 13.1% Weight Loss in Phase 3 SYNCHRONIZE-2 Trial for Obesity and Type 2 Diabetes
Survodutide's Phase 3 SYNCHRONIZE-2 trial showed up to 13.1% weight loss and major A1c improvements in adults with obesity and type 2 diabetes, Boehringer Ingelheim announced.
Read the guide → 📰 Peptide NewsEli Lilly's EloraTZP Combination Shows Up to 23.3% Weight Loss in Phase 2b Trial, Outperforming Tirzepatide Alone
Eli Lilly's Phase 2b trial combining the amylin analog eloralintide with tirzepatide (EloraTZP) produced up to 23.3% weight loss in adults with obesity and type 2 diabetes, presented at EASD 2026.
Read the guide → 📰 Peptide NewsNovo Nordisk Licenses Hengrui's Early-Stage Oral GLP-1/GIP Candidate HRS-1596 in Deal Worth Up to $2.6 Billion
Novo Nordisk will pay Chinese drugmaker Hengrui Pharmaceutical $300 million upfront, with up to $2.6 billion in milestones, for global rights (outside China) to HRS-1596, an oral GLP-1/GIP obesity candidate that hasn't yet entered human trials.
Read the guide → 📰 Peptide NewsZealand Pharma Publishes Full Phase 2 Petrelintide Results in The Lancet, Presents New Data at EASD 2026
Zealand Pharma and Roche published complete ZUPREME-1 Phase 2 results for the amylin analog petrelintide in The Lancet Diabetes & Endocrinology, with new data presented at EASD 2026.
Read the guide → 📰 Peptide NewsEli Lilly: 700,000 Seniors Have Started GLP-1s Under Medicare's Bridge Program, With Lilly Capturing 70%
Eli Lilly CEO Dave Ricks says 700,000 seniors have started GLP-1 obesity drugs since Medicare's bridge program launched, with Lilly capturing 70% of those patients and a third of new oral GLP-1 starts.
Read the guide → 📰 Peptide NewsWADA Keeps GLP-1 Drugs Off the 2027 Prohibited List, Adds Them to Its Monitoring Programme
The World Anti-Doping Agency decided against banning semaglutide and tirzepatide from sport for 2027, opting instead to track usage through its Monitoring Programme.
Read the guide → 📰 Peptide NewsNew EASD 2026 Data Suggests GLP-1 Eligibility Could Extend to Millions More Overweight Adults
A Danish analysis of over 300,000 people, presented at EASD 2026 in Milan, argues that roughly half of adults with overweight but not obesity face heart-disease risk similar to those already eligible for GLP-1 therapy.
Read the guide → 📰 Peptide NewsFDA Warning Letters Hit Three More Peptide Sellers Over Unapproved GLP-1, PT-141, and Recovery Peptide Products
Peptide Partners, Peak Performance Peptides, and NuScience Peptides all received FDA warning letters dated August 24, 2026, in the agency's ongoing crackdown on unapproved peptide sales.
Read the guide → 📰 Peptide NewsNovo Nordisk Licenses Nanexa's Long-Acting Injectable Coating Technology in Deal Worth Up to $1.33 Billion
Novo Nordisk has signed an exclusive global license for Nanexa's PharmaShell coating technology, a drug-delivery platform aimed at extending how long peptide injectables act in the body.
Read the guide → 📰 Peptide NewsZealand Pharma and Roche Launch Phase 3 ZUPREME Trials for Petrelintide, an Amylin Analog for Obesity
Zealand Pharma and Roche began Phase 3 testing of petrelintide, a once-weekly amylin analog, across three trials enrolling roughly 7,000 people with overweight or obesity.
Read the guide → 📰 Peptide NewsStructure Therapeutics' Oral GLP-1 Pill Aleniglipron Shows 16.2% Weight Loss at 72 Weeks, Unveils New Amylin Candidate
New 72-week extension data show Structure Therapeutics' oral GLP-1 pill aleniglipron produced 16.2% weight loss without plateauing, as the company also reported early data on a new amylin/calcitonin candidate.
Read the guide → 📰 Peptide NewsPfizer's Once-Monthly GLP-1 Candidate Shows Up to 12.3% Weight Loss in Phase 2b Trial
Pfizer's ultra-long-acting GLP-1 candidate PF-08653944 produced up to 12.3% placebo-adjusted weight loss with monthly maintenance dosing.
Read the guide → 📰 Peptide NewsAstraZeneca's Oral GLP-1 Pill Elecoglipron Advances to Phase 3 After Strong Phase 2b Results
AstraZeneca is advancing its once-daily oral GLP-1 candidate elecoglipron into Phase 3 after strong weight-loss and glycemic data.
Read the guide → 📰 Peptide NewsPeptide Vendor Sentenced to Nearly 6 Years in Prison for Illegal "Research Chemical" Sales
A federal judge sentenced a peptide vendor to 70 months in prison in one of the first major criminal prosecutions of the research-chemical peptide market.
Read the guide → 📰 Peptide NewsFDA Approves Onswik, Eli Lilly's Once-Weekly Basal Insulin
The FDA approved Onswik (insulin efsitora alfa) on September 24, 2026, intensifying Eli Lilly's once-weekly insulin rivalry with Novo Nordisk's Awiqli.
Read the guide → 📰 Peptide NewsViking Therapeutics' VK2735 Preserves Up to 97% of Weight Loss With Less-Frequent Dosing, New Data Shows
New maintenance-phase data released September 22, 2026 shows Viking Therapeutics' VK2735 preserved up to 97% of prior weight loss on every-other-week dosing, sending VKTX shares sharply higher.
Read the guide → 📰 Peptide NewsFDA Revises Draft Guidance for 17 Generic Peptide Products, Including Semaglutide and Tirzepatide
The FDA's July 28, 2026 revised draft guidance updates testing and manufacturing expectations for 17 generic peptide drugs, with the public comment period closing September 28, 2026.
Read the guide → 📰 Peptide NewsEli Lilly Sues Six Businesses Over Illegal Sales of Unapproved Retatrutide
Eli Lilly filed six federal lawsuits on August 12, 2026 against peptide sellers, a medical spa, and a compounding pharmacy accused of illegally marketing retatrutide, which remains unapproved and in Phase 3 trials.
Read the guide → 📰 Peptide NewsNovo Nordisk Targets Five "Multi-Blockbuster" Products by 2030 in Post-Wegovy Growth Strategy
At its September 21, 2026 Capital Markets Day, Novo Nordisk laid out a diversification plan beyond semaglutide, targeting five multi-blockbuster drugs by 2030 including new obesity, liver, and blood-disorder peptides.
Read the guide → 📰 Peptide NewsThird Texas Peptide Compounder Recalls Compounded Glutathione Over Endotoxin Contamination
A third Texas compounding pharmacy, Centric Compounding, recalled injectable glutathione products nationwide on September 16, 2026 after elevated endotoxin levels were tied to nine adverse event reports.
Read the guide → 📰 Peptide NewsNew Nature Study Finds Semaglutide Extended Lifespan by 12% in Aging Mice
A UC Berkeley study in aged mice found semaglutide extended median lifespan by roughly 12 percent, and researchers caution the finding is still a long way from a human longevity claim.
Read the guide → 📰 Peptide NewsCagriSema Misses Non-Inferiority Goal Against Tirzepatide in the REDEFINE 4 Trial
Novo Nordisk's head-to-head REDEFINE 4 trial found CagriSema produced strong weight loss but fell short of matching tirzepatide on the trial's primary statistical endpoint.
Read the guide → 📰 Peptide NewsEli Lilly Delays Retatrutide's FDA Application to 2027, Citing Manufacturing Data
Eli Lilly pushed back its planned FDA submission for the triple-agonist drug retatrutide to the first quarter of 2027, citing a need for more manufacturing and quality-control data.
Read the guide → 📰 Peptide NewsTirzepatide Widens Its Lead Over Novo Nordisk's Wegovy Pill in Q2 2026 Earnings
Eli Lilly's second-quarter 2026 earnings showed tirzepatide sales far outpacing Novo Nordisk's oral Wegovy pill, widening the competitive gap between the two obesity-drug makers.
Read the guide → 📰 Peptide NewsFoundayo (Orforglipron) Lowers Cardiovascular Risk in Type 2 Diabetes, New ACHIEVE-4 Data Shows
Eli Lilly's Phase 3 ACHIEVE-4 trial, presented at EASD 2026, found the oral GLP-1 pill Foundayo (orforglipron) reduced major cardiovascular events in adults with type 2 diabetes and elevated heart risk.
Read the guide → 📰 Peptide NewsNovo Nordisk Rebrands to "Novo" as Obesity Drug Competition With Eli Lilly Intensifies
Novo Nordisk announced on September 14, 2026 that it is rebranding to the single name "Novo" as part of a broader strategy reset amid intensifying competition with Eli Lilly.
Read the guide → 📰 Peptide NewsFDA Schedules Second Peptide Advisory Panel for 2027, Adding GHK-Cu, Melanotan II, and Three Others to the Review List
The FDA has scheduled a second Pharmacy Compounding Advisory Committee meeting, expected before the end of February 2027, to evaluate five more peptides for possible legal compounding.
Read the guide → 📰 Peptide NewsRetatrutide's TRIUMPH-2 and TRIUMPH-3 Trials Show Strong Results in Diabetes and Cardiovascular Disease Patients
Eli Lilly's Phase 3 TRIUMPH-2 and TRIUMPH-3 trials report substantial weight loss and A1C improvements for retatrutide in people with type 2 diabetes and established heart disease.
Read the guide → 📰 Peptide NewsEloralintide Plus Tirzepatide Combination Shows 17% Weight Loss in a 16-Week Phase 2 Trial
New Phase 2 data show adding the amylin analog eloralintide to tirzepatide produced greater weight loss than tirzepatide alone over 16 weeks.
Read the guide → 📰 Peptide NewsFDA Announces Workshop on the Generic GLP-1 Drug Pathway
The FDA and its Center for Research on Complex Generics will hold a September workshop addressing how generic versions of GLP-1 drugs like semaglutide and tirzepatide could reach the market.
Read the guide → 📰 Peptide NewsSemaglutide and Tirzepatide Patent Timelines: Why True Generic GLP-1s Are Still Years Away
Patents are only one of several barriers standing between today's brand-name GLP-1 drugs and lower-cost generic versions.
Read the guide → 📰 Peptide NewsNew Peer-Reviewed Review Finds Insufficient Human Evidence Behind BPC-157, TB-500, and Four Other Popular Peptides
A UCLA-led review of 565 studies on six popular research-chemical peptides found the human evidence base is thin and lags far behind the marketing.
Read the guide → 📰 Peptide NewsViking Therapeutics Advances VK2735 Into Phase 3 as an Oral Obesity Pill Program Prepares to Launch
Viking's dual GLP-1/GIP candidate VK2735 has two Phase 3 injectable trials fully enrolled, with an oral tablet Phase 3 program expected later in 2026.
Read the guide → 📰 Peptide NewsMedicare's New $50-a-Month GLP-1 Bridge Program: What It Covers and Who Qualifies
A federal demonstration project caps out-of-pocket costs for certain GLP-1 medications at $50 a month for Medicare Part D enrollees.
Read the guide → 📰 Peptide NewsFDA Approves Oral Wegovy: Novo Nordisk's Semaglutide Pill for Weight Loss
The FDA has approved a high-dose oral semaglutide tablet for weight management, adding a pill option alongside injectable Wegovy.
Read the guide → 📰 Peptide NewsRetatrutide's TRIUMPH-1 Trial Shows Up to 30% Weight Loss in a Phase 3 Obesity Study
Retatrutide's first Phase 3 trial, TRIUMPH-1, reported average weight loss of up to 30.3% at the highest dose over two years.
Read the guide → 📰 Peptide NewsFDA Advisory Panel Votes to Recommend BPC-157, TB-500, and Four Other Peptides for Legal Compounding
An FDA advisory committee voted in July 2026 to recommend BPC-157, TB-500, and four other peptides for legal pharmacy compounding, reversing the agency's own scientific staff.
Read the guide → 📰 Peptide NewsFDA Warns Four Peptide Sellers Over Illegal Marketing of Weight-Loss Peptide Knockoffs
The FDA sent warning letters to four peptide sellers on September 1, 2026 for marketing unapproved compounds resembling retatrutide and semaglutide as human drugs.
Read the guide → 📰 Peptide NewsFDA Approves Orforglipron, the First Oral GLP-1 Pill Without Food or Water Restrictions
The FDA approved Eli Lilly's orforglipron (Foundayo) on April 1, 2026, the first oral GLP-1 medicine for weight management that doesn't require fasting or water restrictions.
Read the guide → 📰 Peptide NewsHow Clinical Trials for New Peptide Drugs Get Designed and Approved
How researchers design a peptide drug trial, from choosing endpoints to getting regulatory sign-off before enrollment even begins.
Read the guide → 📰 Peptide NewsHow International Regulators Treat Peptides Differently Than the FDA
How peptide regulation in the EU, UK, Canada, and Australia compares to the FDA's approach, and why that matters for cross-border purchasing.
Read the guide → 📰 Peptide NewsHow a Drug Moves from Clinical Trial to FDA Approval: A Peptide Case Study
Using tirzepatide's development timeline to illustrate the full path from early trials to FDA approval.
Read the guide → 📰 Peptide NewsHow the Compounding Pharmacy Landscape Is Shifting for Peptides
How increased FDA scrutiny and manufacturer legal action are reshaping which pharmacies compound peptides and how.
Read the guide → 📰 Peptide NewsHow the FDA Regulates Compounded GLP-1 Medications
How the FDA's rules on compounding shift depending on whether a drug is officially in shortage, and what that means for compounded semaglutide and tirzepatide.
Read the guide → 📰 Peptide NewsInsurance Coverage for GLP-1 Medications: Where Policy Stands
An overview of how insurance coverage for GLP-1 medications varies by diagnosis, plan type, and employer decisions.
Read the guide → 📰 Peptide NewsRetatrutide and the Next Generation of GLP-1/GIP/Glucagon Agonists
An overview of retatrutide and the broader trend toward multi-receptor agonist peptides in metabolic drug development.
Read the guide → 📰 Peptide NewsThe Difference Between FDA-Approved, Off-Label, and Unapproved Peptide Use
Clarifying three distinct categories of peptide use that get conflated in casual conversation: approved, off-label, and unapproved.
Read the guide → 📰 Peptide NewsTracking the Research Pipeline: Peptides Currently in Late-Stage Trials
An overview of how to track peptide drugs currently in late-stage clinical trials, and why that's more reliable than following hype.
Read the guide → 📰 Peptide NewsUnderstanding the GLP-1 Drug Shortage: What Happened and Where Things Stand
A plain-language explainer of the GLP-1 shortage, why it happened, and how it reshaped the compounding market.
Read the guide → 📰 Peptide NewsWhat "Research Use Only" Labeling Actually Means Under U.S. Law
What the legal disclaimer on research-chemical peptide vendors actually accomplishes, and what it doesn't protect buyers from.
Read the guide → 📰 Peptide NewsWhat a Black-Box Warning Means and Which Peptides Carry One
What an FDA boxed warning actually signifies, and which peptide-based drugs currently carry one.
Read the guide → 📰 Peptide NewsWhy Peptide Telehealth Companies Face Increasing Scrutiny
Why regulators, medical boards, and manufacturers have increased scrutiny of telehealth companies prescribing peptide therapies.
Read the guide → 📰 Peptide NewsWhy Some Peptides Disappear From the Market Overnight
Why a peptide product can suddenly become unavailable, from FDA enforcement to supplier shutdowns to payment processor bans.
Read the guide → 📰 Peptide NewsWhy the FDA Cracked Down on BPC-157 and TB-500 in Compounded Formulations
Why the FDA determined BPC-157 and TB-500 don't meet the bar for pharmacy compounding, and what that means for their availability.
Read the guide → 📰 Peptide NewsFDA Proposes Permanent Ban on Compounded Semaglutide, Tirzepatide, and Liraglutide
The FDA has proposed a rule permanently barring bulk compounding of semaglutide, tirzepatide, and liraglutide, closing the door even if a future shortage occurs.
Read the guide → 📰 Peptide NewsA New Real-World Study Compares Semaglutide and Tirzepatide on Heart Outcomes
A large real-world cohort study (STEER) found lower cardiovascular event rates with semaglutide than tirzepatide, but the results come with important caveats.
Read the guide → 📰 Peptide NewsEli Lilly's Eloralintide Shows Up to 20% Weight Loss in a Phase 2 Obesity Trial
Eli Lilly's amylin-agonist candidate eloralintide produced up to 20.1% weight loss in a Phase 2 trial, with Phase 3 studies now planned.
Read the guide →